Developing drugs in cancer-related bone pain

Crit Rev Oncol Hematol. 2017 Nov:119:66-74. doi: 10.1016/j.critrevonc.2017.08.005. Epub 2017 Aug 25.

Abstract

Introduction: Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon.

Methods: The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered.

Conclusions: In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.

Keywords: Bone metastases; Cancer pain; Nerve growth factor; Opioids; RANK; RANK-L.

Publication types

  • Review

MeSH terms

  • Analgesics, Opioid / pharmacology
  • Analgesics, Opioid / therapeutic use*
  • Bone Neoplasms / physiopathology
  • Bone Neoplasms / secondary*
  • Cancer Pain / drug therapy*
  • Humans
  • Quality of Life
  • Randomized Controlled Trials as Topic

Substances

  • Analgesics, Opioid